B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Hemophilia B

Trial Profile

B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Hemophilia B

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Eftrenonacog alfa (Primary) ; Nonacog alfa
  • Indications Haemophilia B
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms B-LONG
  • Sponsors Biogen Idec
  • Most Recent Events

    • 11 Dec 2017 Results published in the Bioverativ media release.
    • 27 Nov 2017 According to a Bioverativ media release, based on interim data from the B-YOND trial and final data from the Kids B-LONG pediatric study the U.S. Food and Drug Administration (FDA) has approved updated labeling for ALPROLIX the leading extended half-life therapy for the treatment of adults and children with hemophilia B.
    • 01 Nov 2017 According to a Bioverativ media release, longitudinal analysis from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top